CRISPR Therapeutics AG — Director's Dealing 2026

Mar 17, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2026-03-14

Reporting Person: Patel Naimish (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-03-14	Common Shares	M	8125	—	Acquired	16293	Direct
2026-03-16	Common Shares	S	3150	$48.26	Disposed	13143	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-03-14	Restricted Stock Units	$	M	8125	Disposed		Common Shares (8125)	Direct

Footnotes

F1: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3: Includes 592 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.

F4: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

F5: This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.